Johnson &amp; Johnson (NYSE:JNJ) on Wednesday reported a fourth-quarter 2025 adjusted earnings of $2.46 per share, up 20.6% year over year, beating the consensus of $2.44.



The pharmaceutical and medtech giant reported sales of $24.56 billion, up 9.1% year over year and beating the consensus of $24.16 billion.



Operational growth was 7.1%, and adjusted operational growth was 6.1%.



Innovative Medicine sales increased 10% or 7.9% operationally to $15.76 billion. Fiscal 2025 sales increased 6% to $60.40 billion.



2025 operational sales grew 5.3%, with net acquisitions and divestitures positively impacting growth by 1.2% primarily due to Caplyta.



Growth was driven primarily by Darzalex (daratumumab), Carvykti (ciltacabtagene autoleucel), Erleada (apalutamide), and Rybrevant/Lazcluze in oncology, Tremfya (guselkumab) and Simponi/Simponi Aria in immunology, and Spravato (esketamine) in neuroscience.



Growth was partially offset by an approximate (1,040) basis points impact from Stelara in Immunology.



Cancer drug sales increased to $6.86 billion, up 24.8% (+21.9% operational). Immunology sales declined to $3.86 billion, a 8.9% decrease (or 10.3% on an operational basis).



MedTech sales increased 7.5% to $8.80 billion. 2025 operational sales grew 5.4%, with net acquisitions and divestitures positively impacting growth by 1.1% primarily due to Shockwave.



Growth was driven primarily by electrophysiology products and Abiomed in Cardiovascular, and wound closure products in General Surgery.



Johnson &amp; Johnson, in its earnings presentation, highlighted that its cancer cell therapy Carvykti and Shockwave each generated annual sales of over $1 billion.



The company said it has 28 platforms with at least $1 billion in annual revenues.



<h2>Outlook</h2>



Johnson &amp; Johnson issued fiscal 2026 adjusted earnings guidance of $11.43-$11.63, compared to the consensus of $11.45.



The company expects 2026 sales of $99.50 billion-$100.5 billion compared to the consensus of $98.89 billion.



Price Action: Johnson &amp; Johnson shares were down 0.90% at $216.24 during premarket trading on Wednesday. The stock is trading near its 52-week high of $220.11, according to Benzinga Pro data.



Photo by Tada Images via Shutterstock

ARKG

Johnson & Johnson reported Q4 2025 adjusted earnings of $2.46 per share, exceeding estimates, with sales of $24.56 billion, up 9.1% year-over-year. The company anticipates 2026 sales to reach $99.50-$100.5 billion, surpassing consensus expectations. Key growth drivers included oncology and MedTech products, while immunology sales declined. Shares are near a 52-week high, trading at $216.24, down 0.90% in premarket.

benzinga_article

iShares US Pharma

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

iShares US Medical Devices

SPDR S&P Health Equip

iShares Global Healthcare

Johnson & Johnson

VG Health

Johnson & Johnson Expects 2026 Sales To Hit Almost $100 Billion